Jyothis T. George
Amgen (United States)(US)Tarzana Treatment Centers(US)The White House(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Cardiovascular Function and Risk Factors
Most-Cited Works
- → Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk(2018)1,061 cited
- → How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial(2017)735 cited
- → Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes(2019)586 cited
- → The kisspeptin-GnRH pathway in human reproductive health and disease(2014)482 cited
- → Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease(2017)467 cited
- → Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial(2019)346 cited